Core Viewpoint - The company has completed the cancellation of 11.4599 million shares, reducing its total share capital from 911 million to 899 million shares, which aims to enhance shareholder value and long-term investment potential [1][4] Group 1: Share Buyback and Cancellation - The share cancellation was a strategic decision made in October, shifting from an employee stock ownership plan to direct cancellation, reflecting the company's commitment to shareholder interests [1][3] - The company spent approximately 79.9967 million yuan on the repurchase, with an average price of 6.98 yuan per share, which will directly improve key financial metrics such as earnings per share [1][3] Group 2: Business Strategy and Acquisitions - The company has acquired a 20% stake in JunTai Pharmaceutical for 25 million yuan, achieving 100% ownership, which allows for better integration of resources in the pharmaceutical sector [2] - This acquisition aligns with the company's strategy to strengthen its position in the pharmaceutical and chemical industry, laying a solid foundation for long-term growth [2] Group 3: Industry Context and Future Outlook - The Ministry of Industry and Information Technology has set a target for the petrochemical industry to achieve an average annual growth of over 5% from 2025 to 2026, emphasizing supply-side structural reforms [2] - The company is well-positioned to benefit from industry consolidation and policy improvements, particularly in the pharmaceutical CDMO sector, which is expected to gain market share amid industry changes [3][4]

Core Viewpoint - The company has completed the cancellation of repurchased shares, which amounts to 11,459,900 shares, representing 1.26% of the total share capital before cancellation, reducing the total share capital from 911,333,117 shares to 899,873,217 shares [2][6]. Summary by Sections Repurchase and Cancellation Details - The company approved a share repurchase plan on February 28, 2025, intending to buy back A-shares at a price not exceeding 9.50 RMB per share, with a total fund of no less than 40 million RMB and no more than 80 million RMB [2]. - The company completed the repurchase of 11,459,900 shares by March 26, 2025, with an average price of 6.98 RMB per share, totaling approximately 80 million RMB [4]. - The cancellation of the repurchased shares was confirmed by the China Securities Depository and Clearing Corporation on November 10, 2025 [6]. Changes in Shareholding Structure - Following the cancellation, the controlling shareholder, Ms. Miao Jinxiang, saw her shareholding increase from 25.74% to 26.06% due to the reduction in total shares, which is a passive change and does not involve any active increase or decrease in her holdings [2][6]. Compliance and Future Actions - The cancellation process complies with relevant laws and regulations, ensuring no significant impact on the company's financial status, R&D capabilities, or operational capacity [6]. - The company will proceed with the necessary registration and documentation changes following the cancellation of shares [7].

证券代码：002250 证券简称：联化科技 公告编号：2025-054 联化科技股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、联化科技股份有限公司（以下简称"公司"）本次注销的回购股份数量为 11,459,900 股，占公司本次回购股份注销前总股本的 1.26%，本次注销完成后， 公司总股本由 911,333,117 股变更为 899,873,217 股。 2、公司于 2025 年 3 月 12 日首次通过股票回购专用证券账户以集中竞价交 易方式回购股份，回购股份数量为 1,127,000 股，占公司目前总股本的 0.1237%， 最高成交价为 6.97 元/股，最低成交价为 6.97 元/股，成交总金额为 7,855,190.00 元（不含交易费用）。本次回购股份资金来源为公司自有资金和自筹资金，回购 价格未超过回购方案中拟定的价格上限 9.50 元/股。具体内容详见公司 2025 年 3 月 13 日于《证券时报》《上海证券报》及巨潮资讯网（www.cninfo.com.cn）披露 的《 ...

Core Insights - The agricultural chemical sector experienced a slight increase of 0.24% on November 11, with Lanfeng Biochemical leading the gains [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Stock Performance - Lanfeng Biochemical (002513) closed at 9.50, up 7.22% with a trading volume of 965,400 shares [1] - Baiao Chemical (603360) closed at 33.19, up 4.90% with a trading volume of 201,500 shares [1] - Other notable performers include: - Lianhua Technology (002250) at 13.40, up 3.40% [1] - Chuanjinno (300505) at 25.35, up 2.84% [1] - Yuntu Holdings (002539) at 12.06, up 2.73% [1] Capital Flow - The agricultural chemical sector saw a net outflow of 1.155 billion yuan from institutional investors, while retail investors contributed a net inflow of 713 million yuan [2] - Notable capital flows include: - Lianhua Technology (002250) with a net inflow of 101 million yuan from institutional investors [3] - Lanfeng Biochemical (002513) with a net outflow of 74 million yuan from retail investors [3] - Chuanjinno (300505) with a net inflow of 15.7 million yuan from institutional investors [3]

Core Viewpoint - The company, Lianhua Technology (002250.SZ), has stated that it currently has no plans for investments or acquisitions of upstream or downstream companies to accelerate its development progress [1] Group 1 - The company is not pursuing any investment or acquisition strategies at this time [1]

格隆汇11月10日丨联化科技(002250.SZ)在投资者互动平台表示，公司暂无投资或并购上下游公司以加 快发展进度的计划。 ...

Core Viewpoint - Company is currently in the technical improvement phase of its lithium hexafluorophosphate project, focusing on systematic process development and continuous optimization of product competitiveness [1] Group 1 - Company is following a systematic process development approach for its lithium hexafluorophosphate project [1] - Continuous improvement efforts are being made to enhance product competitiveness [1]

格隆汇11月5日丨联化科技(002250.SZ)在投资者互动平台表示，公司目前仍在对六氟磷酸锂项目进行技 术改进阶段，公司遵循体系化的工艺开发流程并持续改进优化产品竞争力。 ...

Core Viewpoint - Lianhua Technology's stock price has seen significant growth this year, with a year-to-date increase of 114.21%, despite a recent decline in trading activity [1] Group 1: Stock Performance - As of November 5, Lianhua Technology's stock price was 11.76 yuan per share, with a market capitalization of 10.717 billion yuan [1] - The stock experienced a net outflow of 29.31 million yuan in principal funds, with large orders showing a buy of 43.25 million yuan and a sell of 61.40 million yuan [1] - The stock has risen by 3.70% in the last five trading days, 7.30% in the last 20 days, and 9.40% in the last 60 days [1] Group 2: Company Overview - Lianhua Technology, established on September 14, 1998, and listed on June 19, 2008, operates in three main sectors: pesticides, pharmaceuticals, and functional chemicals [2] - The revenue composition is as follows: pesticides 54.03%, pharmaceuticals 32.32%, functional chemicals 8.42%, equipment and engineering services 4.88%, and others 0.36% [2] - The company is classified under the basic chemicals industry, specifically in pesticide products [2] Group 3: Financial Performance - For the period from January to September 2025, Lianhua Technology reported a revenue of 4.718 billion yuan, reflecting a year-on-year growth of 8.25% [2] - The net profit attributable to shareholders was 316 million yuan, showing a remarkable year-on-year increase of 871.65% [2] - The company has distributed a total of 960 million yuan in dividends since its A-share listing, with 129 million yuan distributed in the last three years [3]

Group 1 - The company is currently in the technical improvement phase of its lithium hexafluorophosphate project and has not yet generated large-scale sales [1]